Modus Therapeutics Holding AB
Developing sevuparin, a polysaccharide for sepsis, septic shock, and chronic inflammation.
MODTX | ST
Overview
Corporate Details
- ISIN(s):
- SE0015987904
- LEI:
- 984500C147FB4EF4A471
- Country:
- Sweden
- Address:
- Olof Palmes gata 29 IV, 111 22 STOCKHOLM
- Website:
- https://modustx.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Modus Therapeutics Holding AB is a biotechnology company focused on developing its proprietary polysaccharide, sevuparin, for diseases with high unmet medical needs. The company's lead candidate is being developed as a potential treatment for severe conditions characterized by systemic inflammation, such as sepsis and septic shock. Other potential applications include addressing states of anemia related to chronic inflammation, for example, in kidney disease. Modus aims to provide innovative therapeutic options for these critical patient populations.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Modus Therapeutics Holding AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Modus Therapeutics Holding AB
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Modus Therapeutics Holding AB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
